Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With Chemotherapy as Neoadjuvant Therapy for cT2N0M0 Early-Stage Oral Squamous Cell Carcinoma: A Multicenter, Randomized Controlled, Open-Label, Superiority, Phase III Clinical Trial

NCT07827872 is registered in ClinicalTrials.gov with caohaotian as lead sponsor.

NCT NCT07827872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07827872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With Chemotherapy as Neoadjuvant Therapy for cT2N0M0 Early-Stage Oral Squamous Cell Carcinoma: A Multicenter, Randomized Controlled, Open-Label, Superiority, Phase III Clinical Trial
Lead sponsor
caohaotian
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2032
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage oral cancer, head and neck squamous cell carcinoma, oral squamous cell carcinoma (oscc)